Table of Content

1. Executive Summary
1.1. Global Systemic Scleroderma Treatment Market Snapshot, 2024 and 2031
1.2. Market Opportunity Assessment, 2024 – 2031, US$ Mn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations
2. Market Overview
2.1. Market Scope and Definition
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Opportunity
2.2.4. Challenges
2.2.5. Key Trends
2.3. Macro-Economic Factors
2.3.1. Global GDP Growth Outlook
2.3.2. Global Healthcare Spending Outlook
2.4. COVID-19 Impact Analysis
2.5. Forecast Factors – Relevance and Impact
3. Value Added Insights
3.1. Regulatory Landscape
3.2. Product Adoption Analysis
3.3. Key Deals and Mergers
3.4. Disease Epidemiology
3.5. Pipeline Assessment
3.6. PESTLE Analysis
3.7. Porter’s Five Force Analysis
4. Global Systemic Scleroderma Treatment Market Outlook: Historical (2018 – 2023) and Forecast (2024 – 2031)
4.1. Key Highlights
4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
4.1.2. Absolute $ Opportunity
4.2. Market Size (US$ Mn) Analysis and Forecast
4.2.1. Historical Market Size (US$ Mn) Analysis, 2018-2023
4.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2024–2031
4.3. Global Systemic Scleroderma Treatment Market Outlook: Target Organ
4.3.1. Introduction / Key Findings
4.3.2. Historical Market Size (US$ Mn) Analysis, By Target Organ, 2018 – 2023
4.3.3. Current Market Size (US$ Mn) Analysis and Forecast, By Target Organ, 2024 – 2031
4.3.3.1. Skin Fibrosis
4.3.3.2. Musculoskeletal
4.3.3.3. Digital Ulcers
4.3.3.4. Pulmonary Arterial Hypertension
4.3.3.5. Gastrointestinal
4.3.3.6. Pulmonary Fibrosis
4.3.3.7. Scleroderma Renal Crisis
4.3.4. Market Attractiveness Analysis: Target Organ
4.4. Global Systemic Scleroderma Treatment Market Outlook: Treatment Type
4.4.1. Introduction / Key Findings
4.4.2. Historical Market Size (US$ Mn) Analysis, By Treatment Type, 2018 – 2023
4.4.3. Current Market Size (US$ Mn) Analysis and Forecast, By Treatment Type, 2024 – 2031
4.4.3.1. Drug Therapy
4.4.3.1.1. Corticosteroids
4.4.3.1.2. Immunosuppressants
4.4.3.1.3. Nonsteroidal AntiInflammatory Drugs
4.4.3.1.4. Calcium Channel Blockers
4.4.3.1.5. Proton Pump Inhibitors
4.4.3.1.6. TNF Inhibitors
4.4.3.1.7. Endothelin Receptor Antagonists
4.4.3.1.8. Phosphodiesterase Type 5 Inhibitors
4.4.3.1.9. Angiotensin-Converting Enzyme
4.4.3.2. Hematopoietic Stem Cell Transplantation (HSCT)
4.4.4. Market Attractiveness Analysis: Treatment Type
4.5. Global Systemic Scleroderma Treatment Market Outlook: Route of Administration
4.5.1. Introduction / Key Findings
4.5.2. Historical Market Size (US$ Mn) Analysis, By Route of Administration, 2018 – 2023
4.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Route of Administration, 2024 – 2031
4.5.3.1. Injectable
4.5.3.2. Oral
4.5.3.3. Topical
4.5.4. Market Attractiveness Analysis: Route of Administration
4.6. Global Systemic Scleroderma Treatment Market Outlook: Distribution Channel
4.6.1. Introduction / Key Findings
4.6.2. Historical Market Size (US$ Mn) Analysis, By Distribution Channel, 2018 – 2023
4.6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2024 – 2031
4.6.3.1. Hospital Pharmacies
4.6.3.2. Specialty Clinics
4.6.3.3. Retail Pharmacies
4.6.3.4. Online Pharmacies
4.6.4. Market Attractiveness Analysis: Distribution Channel
5. Global Systemic Scleroderma Treatment Market Outlook: Region
5.1. Key Highlights
5.2. Historical Market Size (US$ Mn) Analysis, By Region, 2018 – 2023
5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2024 – 2031
5.3.1. North America
5.3.2. Europe
5.3.3. East Asia
5.3.4. South Asia and Oceania
5.3.5. Latin America
5.3.6. Middle East & Africa
5.4. Market Attractiveness Analysis: Region
6. North America Systemic Scleroderma Treatment Market Outlook: Historical (2018 – 2023) and Forecast (2024 – 2031)
6.1. Key Highlights
6.2. Historical Market Size (US$ Mn) Analysis, By Market, 2018 – 2023
6.2.1. By Country
6.2.2. By Target Organ
6.2.3. By Treatment Type
6.2.4. By Route of Administration
6.2.5. By Distribution Channel
6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024 – 2031
6.3.1. U.S.
6.3.2. Canada
6.4. Current Market Size (US$ Mn) Analysis and Forecast, By Target Organ, 2024 – 2031
6.4.1. Skin Fibrosis
6.4.2. Musculoskeletal
6.4.3. Digital Ulcers
6.4.4. Pulmonary Arterial Hypertension
6.4.5. Gastrointestinal
6.4.6. Pulmonary Fibrosis
6.4.7. Scleroderma Renal Crisis
6.5. Current Market Size (US$ Mn) Analysis and Forecast, By Treatment Type, 2024 – 2031
6.5.1. Drug Therapy
6.5.1.1. Corticosteroids
6.5.1.2. Immunosuppressants
6.5.1.3. Nonsteroidal AntiInflammatory Drugs
6.5.1.4. Calcium Channel Blockers
6.5.1.5. Proton Pump Inhibitors
6.5.1.6. TNF Inhibitors
6.5.1.7. Endothelin Receptor Antagonists
6.5.1.8. Phosphodiesterase Type 5 Inhibitors
6.5.1.9. Angiotensin-Converting Enzyme
6.5.2. Hematopoietic Stem Cell Transplantation (HSCT)
6.6. Current Market Size (US$ Mn) Analysis and Forecast, By Route of Administration, 2024 – 2031
6.6.1. Injectable
6.6.2. Oral
6.6.3. Topical
6.7. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2024 – 2031
6.7.1. Hospital Pharmacies
6.7.2. Specialty Clinics
6.7.3. Retail Pharmacies
6.7.4. Online Pharmacies
6.8. Market Attractiveness Analysis
7. Europe Systemic Scleroderma Treatment Market Outlook: Historical (2018 – 2023) and Forecast (2024 – 2031)
7.1. Key Highlights
7.2. Historical Market Size (US$ Mn) Analysis, By Market, 2018 – 2023
7.2.1. By Country
7.2.2. By Target Organ
7.2.3. By Treatment Type
7.2.4. By Route of Administration
7.2.5. By Distribution Channel
7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024 – 2031
7.3.1. Germany
7.3.2. France
7.3.3. U.K.
7.3.4. Italy
7.3.5. Spain
7.3.6. Russia
7.3.7. Türkiye
7.3.8. Rest of Europe
7.4. Current Market Size (US$ Mn) Analysis and Forecast, By Target Organ, 2024 – 2031
7.4.1. Skin Fibrosis
7.4.2. Musculoskeletal
7.4.3. Digital Ulcers
7.4.4. Pulmonary Arterial Hypertension
7.4.5. Gastrointestinal
7.4.6. Pulmonary Fibrosis
7.4.7. Scleroderma Renal Crisis
7.5. Current Market Size (US$ Mn) Analysis and Forecast, By Treatment Type, 2024 – 2031
7.5.1. Drug Therapy
7.5.1.1. Corticosteroids
7.5.1.2. Immunosuppressants
7.5.1.3. Nonsteroidal AntiInflammatory Drugs
7.5.1.4. Calcium Channel Blockers
7.5.1.5. Proton Pump Inhibitors
7.5.1.6. TNF Inhibitors
7.5.1.7. Endothelin Receptor Antagonists
7.5.1.8. Phosphodiesterase Type 5 Inhibitors
7.5.1.9. Angiotensin-Converting Enzyme
7.5.2. Hematopoietic Stem Cell Transplantation (HSCT)
7.6. Current Market Size (US$ Mn) Analysis and Forecast, By Route of Administration, 2024 – 2031
7.6.1. Injectable
7.6.2. Oral
7.6.3. Topical
7.7. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2024 – 2031
7.7.1. Hospital Pharmacies
7.7.2. Specialty Clinics
7.7.3. Retail Pharmacies
7.7.4. Online Pharmacies
7.8. Market Attractiveness Analysis
8. East Asia Systemic Scleroderma Treatment Market Outlook: Historical (2018 – 2023) and Forecast (2024 – 2031)
8.1. Key Highlights
8.2. Historical Market Size (US$ Mn) Analysis, By Market, 2018 – 2023
8.2.1. By Country
8.2.2. By Target Organ
8.2.3. By Treatment Type
8.2.4. By Route of Administration
8.2.5. By Distribution Channel
8.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024 – 2031
8.3.1. China
8.3.2. Japan
8.3.3. South Korea
8.4. Current Market Size (US$ Mn) Analysis and Forecast, By Target Organ, 2024 – 2031
8.4.1. Skin Fibrosis
8.4.2. Musculoskeletal
8.4.3. Digital Ulcers
8.4.4. Pulmonary Arterial Hypertension
8.4.5. Gastrointestinal
8.4.6. Pulmonary Fibrosis
8.4.7. Scleroderma Renal Crisis
8.5. Current Market Size (US$ Mn) Analysis and Forecast, By Treatment Type, 2024 – 2031
8.5.1. Drug Therapy
8.5.1.1. Corticosteroids
8.5.1.2. Immunosuppressants
8.5.1.3. Nonsteroidal AntiInflammatory Drugs
8.5.1.4. Calcium Channel Blockers
8.5.1.5. Proton Pump Inhibitors
8.5.1.6. TNF Inhibitors
8.5.1.7. Endothelin Receptor Antagonists
8.5.1.8. Phosphodiesterase Type 5 Inhibitors
8.5.1.9. Angiotensin-Converting Enzyme
8.5.2. Hematopoietic Stem Cell Transplantation (HSCT)
8.6. Current Market Size (US$ Mn) Analysis and Forecast, By Route of Administration, 2024 – 2031
8.6.1. Injectable
8.6.2. Oral
8.6.3. Topical
8.7. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2024 – 2031
8.7.1. Hospital Pharmacies
8.7.2. Specialty Clinics
8.7.3. Retail Pharmacies
8.7.4. Online Pharmacies
8.8. Market Attractiveness Analysis
9. South Asia & Oceania Systemic Scleroderma Treatment Market Outlook: Historical (2018 – 2023) and Forecast (2024 – 2031)
9.1. Key Highlights
9.2. Historical Market Size (US$ Mn) Analysis, By Market, 2018 – 2023
9.2.1. By Country
9.2.2. By Target Organ
9.2.3. By Treatment Type
9.2.4. By Route of Administration
9.2.5. By Distribution Channel
9.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024 – 2031
9.3.1. India
9.3.2. Southeast Asia
9.3.3. ANZ
9.3.4. Rest of South Asia & Oceania
9.4. Current Market Size (US$ Mn) Analysis and Forecast, By Target Organ, 2024 – 2031
9.4.1. Skin Fibrosis
9.4.2. Musculoskeletal
9.4.3. Digital Ulcers
9.4.4. Pulmonary Arterial Hypertension
9.4.5. Gastrointestinal
9.4.6. Pulmonary Fibrosis
9.4.7. Scleroderma Renal Crisis
9.5. Current Market Size (US$ Mn) Analysis and Forecast, By Treatment Type, 2024 – 2031
9.5.1. Drug Therapy
9.5.1.1. Corticosteroids
9.5.1.2. Immunosuppressants
9.5.1.3. Nonsteroidal AntiInflammatory Drugs
9.5.1.4. Calcium Channel Blockers
9.5.1.5. Proton Pump Inhibitors
9.5.1.6. TNF Inhibitors
9.5.1.7. Endothelin Receptor Antagonists
9.5.1.8. Phosphodiesterase Type 5 Inhibitors
9.5.1.9. Angiotensin-Converting Enzyme
9.5.2. Hematopoietic Stem Cell Transplantation (HSCT)
9.6. Current Market Size (US$ Mn) Analysis and Forecast, By Route of Administration, 2024 – 2031
9.6.1. Injectable
9.6.2. Oral
9.6.3. Topical
9.7. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2024 – 2031
9.7.1. Hospital Pharmacies
9.7.2. Specialty Clinics
9.7.3. Retail Pharmacies
9.7.4. Online Pharmacies
9.8. Market Attractiveness Analysis
10. Latin America Systemic Scleroderma Treatment Market Outlook: Historical (2018 – 2023) and Forecast (2024 – 2031)
10.1. Key Highlights
10.2. Historical Market Size (US$ Mn) Analysis, By Market, 2018 – 2023
10.2.1. By Country
10.2.2. By Target Organ
10.2.3. By Treatment Type
10.2.4. By Route of Administration
10.2.5. By Distribution Channel
10.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024 – 2031
10.3.1. Brazil
10.3.2. Mexico
10.3.3. Rest of Latin America
10.4. Current Market Size (US$ Mn) Analysis and Forecast, By Target Organ, 2024 – 2031
10.4.1. Skin Fibrosis
10.4.2. Musculoskeletal
10.4.3. Digital Ulcers
10.4.4. Pulmonary Arterial Hypertension
10.4.5. Gastrointestinal
10.4.6. Pulmonary Fibrosis
10.4.7. Scleroderma Renal Crisis
10.5. Current Market Size (US$ Mn) Analysis and Forecast, By Treatment Type, 2024 – 2031
10.5.1. Drug Therapy
10.5.1.1. Corticosteroids
10.5.1.2. Immunosuppressants
10.5.1.3. Nonsteroidal AntiInflammatory Drugs
10.5.1.4. Calcium Channel Blockers
10.5.1.5. Proton Pump Inhibitors
10.5.1.6. TNF Inhibitors
10.5.1.7. Endothelin Receptor Antagonists
10.5.1.8. Phosphodiesterase Type 5 Inhibitors
10.5.1.9. Angiotensin-Converting Enzyme
10.5.2. Hematopoietic Stem Cell Transplantation (HSCT)
10.6. Current Market Size (US$ Mn) Analysis and Forecast, By Route of Administration, 2024 – 2031
10.6.1. Injectable
10.6.2. Oral
10.6.3. Topical
10.7. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2024 – 2031
10.7.1. Hospital Pharmacies
10.7.2. Specialty Clinics
10.7.3. Retail Pharmacies
10.7.4. Online Pharmacies
10.8. Market Attractiveness Analysis
11. Middle East & Africa Systemic Scleroderma Treatment Market Outlook: Historical (2018 – 2023) and Forecast (2024 – 2031)
11.1. Key Highlights
11.2. Historical Market Size (US$ Mn) Analysis, By Market, 2018 – 2023
11.2.1. By Country
11.2.2. By Target Organ
11.2.3. By Treatment Type
11.2.4. By Route of Administration
11.2.5. By Distribution Channel
11.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024 – 2031
11.3.1. GCC Countries
11.3.2. Egypt
11.3.3. South Africa
11.3.4. Northern Africa
11.3.5. Rest of Middle East & Africa
11.4. Current Market Size (US$ Mn) Analysis and Forecast, By Target Organ, 2024 – 2031
11.4.1. Skin Fibrosis
11.4.2. Musculoskeletal
11.4.3. Digital Ulcers
11.4.4. Pulmonary Arterial Hypertension
11.4.5. Gastrointestinal
11.4.6. Pulmonary Fibrosis
11.4.7. Scleroderma Renal Crisis
11.5. Current Market Size (US$ Mn) Analysis and Forecast, By Treatment Type, 2024 – 2031
11.5.1. Drug Therapy
11.5.1.1. Corticosteroids
11.5.1.2. Immunosuppressants
11.5.1.3. Nonsteroidal AntiInflammatory Drugs
11.5.1.4. Calcium Channel Blockers
11.5.1.5. Proton Pump Inhibitors
11.5.1.6. TNF Inhibitors
11.5.1.7. Endothelin Receptor Antagonists
11.5.1.8. Phosphodiesterase Type 5 Inhibitors
11.5.1.9. Angiotensin-Converting Enzyme
11.5.2. Hematopoietic Stem Cell Transplantation (HSCT)
11.6. Current Market Size (US$ Mn) Analysis and Forecast, By Route of Administration, 2024 – 2031
11.6.1. Injectable
11.6.2. Oral
11.6.3. Topical
11.7. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2024 – 2031
11.7.1. Hospital Pharmacies
11.7.2. Specialty Clinics
11.7.3. Retail Pharmacies
11.7.4. Online Pharmacies
11.8. Market Attractiveness Analysis
12. Competition Landscape
12.1. Market Share Analysis, 2023
12.2. Market Structure
12.2.1. Competition Intensity Mapping By Market
12.2.2. Competition Dashboard
12.3. Company Profiles (Details – Overview, Financials, Strategy, Recent Developments)
12.3.1. Pfizer Inc.
12.3.1.1. Overview
12.3.1.2. Segments and Products
12.3.1.3. Key Financials
12.3.1.4. Market Developments
12.3.1.5. Market Strategy
12.3.2. Novartis AG
12.3.3. GlaxoSmithKline plc.
12.3.4. Sanofi SA
12.3.5. Lupin Ltd
12.3.6. Cipla Ltd
12.3.7. Teva Pharmaceuticals
12.3.8. Johnson & Johnson Services Inc.
12.3.9. Bayer Healthcare LLC
12.3.10. F. Hoffmann-La Roche Ltd
12.3.11. Others
13. Appendix
13.1. Research Methodology
13.2. Research Assumptions
13.3. Acronyms and Abbreviations